Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida – 8 September 2022 – Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a consequence of failed early detection. Professional societies recommend semi‐annual HCC screening in at‐risk patients with chronic liver disease to increase the likelihood of curative treatment receipt and improve survival.
Christopher L. Bowlus, Lionel Arrivé, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff, James H. Tabibian, David N. Assis – 8 September 2022
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente – 8 September 2022
Octavi Bassegoda, Jesús Rivera‐Esteban, Isabel Serra, Rosa Morillas, Teresa Broquetas, Mercedes Vergara, Adrià Rodriguez, Carles Aracil, Silvia Virolés, Jose A. Carrión, Albert Pardo, Sergio Rodríguez‐Tajes, Miquel Serra‐Burriel, Juan M. Pericàs, Salvador Augustin, Pere Ginès, Isabel Graupera – 7 September 2022 – The natural history of compensated cirrhosis due to nonalcoholic fatty liver disease (NAFLD) has not been completely characterized.
Daniel H. Leung, Sridevi Devaraj, Nathan P. Goodrich, Xinpu Chen, Deepthi Rajapakshe, Wen Ye, Victor Andreev, Charles G. Minard, Danielle Guffey, Jean P. Molleston, Lee M. Bass, Saul J. Karpen, Binita M. Kamath, Kasper S. Wang, Shikha S. Sundaram, Philip Rosenthal, Patrick McKiernan, Kathleen M. Loomes, M. Kyle Jensen, Simon P. Horslen, Jorge A. Bezerra, John C. Magee, Robert M. Merion, Ronald J. Sokol, Benjamin L. Shneider, The Childhood Liver Disease Research Network – 6 September 2022
Alexander Chaidez, Zhaoxing Pan, Shikha S. Sundaram, Julia Boster, Mark Lovell, Ronald J. Sokol, Cara L. Mack – 6 September 2022 – Vibration controlled transient elastography (FibroScan) is used to predict the severity of liver fibrosis and steatosis. In pediatrics, few studies have been performed directly comparing liver histologic features with FibroScan liver stiffness measurements (LSMs) and controlled attenuation parameters (CAPs).
Marlene Reincke, Michael Schultheiss, Michael Doppler, Niklas Verloh, Wibke Uller, Lukas Sturm, Robert Thimme, Christian Goetz, Dominik Bettinger – 4 September 2022 – Transarterial radioembolization (TARE) is a well‐established therapy for intermediate and advanced tumor stages of hepatocellular carcinoma (HCC). Treatment‐associated toxicities are rare. Previous studies have outlined that the prognosis after TARE is determined primarily by tumor stage and liver function. The subset of patients benefiting from TARE remains to be defined.
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai‐Hung Wong, Leon A. Adams, Victor Lédinghen, Silvia Sookoian, Vincent Wai‐Sun Wong – 4 September 2022 – NAFLD has become a major public health problem for more than 2 decades with a growing prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease burden of NAFLD differs across geographical regions and ethnicities.
Zhihui Duan – 4 September 2022